Phaseline

Companies › Liaoning Chengda Biotechnology

Liaoning Chengda Biotechnology: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 4; Vaccines, Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Liaoning Chengda Inactivated Japanese Encephalitis Vaccine
Inactivated Japanese encephalitis virus vaccine
–Phase 4Japanese EncephalitisDec 2026
Japanese Encephalitis Vaccine (Vero Cell), Inactivated
Inactivated virus vaccine
–Phase 4Japanese Encephalitis VaccineDec 2030
Japanese Encephalitis Vaccine, Live
Live attenuated virus vaccine
–Phase 4Japanese Encephalitis VaccineDec 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06678373Liaoning Chengda Inactivated Japanese Encephalitis VaccinePhase 4Japanese EncephalitisInfectious diseaseDec 2026
NCT06825312Japanese Encephalitis Vaccine (Vero Cell), InactivatedPhase 4Japanese Encephalitis VaccineVaccinesDec 2030
NCT06825312Japanese Encephalitis Vaccine, LivePhase 4Japanese Encephalitis VaccineVaccinesDec 2030

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

BioNet-Asia Sinovac Biotech Xiamen Innovax Biotech National Vaccine and Serum Institute, China ARJ Medical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.